Skip to main content
SpringerLink
Log in

Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Brugada Syndrome Treatment

  • Original Paper
  • Published:
Journal of Medical Systems Aims and scope Submit manuscript

Abstract

Brugada syndrome is characterized by an ST-segment elevation in the right precordial ECG leads and a high incidence of sudden death in patients with structurally normal hearts. Some trials have demonstrated that the cost-effectiveness of ICD implantation treatment in patients with structurally abnormal hearts is more favorable than that of control treatment. We used Treeage pro 2005 to estimate costs and survival among the Brugada syndrome patients who received either an ICD or were treated by control therapy of Ito-blocking properties (quinidine) or β-blockers (propranolol). In conclusion, our analysis suggests that prophylactic implantation of an ICD has good cost-effectiveness in patients with Brugada syndrome who are at high risk of sudden death. ICD treatment has shown a cost-effectiveness ratio below $9,591 per QALY gained from trials of defibrillator vs β-blockers for Unexplained Death in Thailand (DEBUT). The control therapy of quinidine may be a good choice for patients who are infants or living in developing countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Nademanee, K., Veerakul, G., Nimmannit, S., et al., Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 96:2595–2600, 1997.

    Google Scholar 

  2. Miyasaka, Y., Tsuji, H., Yamada, K., Tokunaga, S., Saito, D., Imuro, Y., Matsumoto, N., and Iwasaka, T., Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J. Am. Coll. Cardiol. 38:771–774, 2001.

    Article  Google Scholar 

  3. Hermida, J. S., Lemoine, J. L., Aoun, F. B., Jarry, G., Rey, J. L., and Quiret, J. C., Prevalence of the Brugada syndrome in an apparently healthy population. Am. J. Cardiol. 86:91–94, 2000.

    Article  Google Scholar 

  4. Brugada, P., and Brugada J., Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J. Am. Coll. Cardiol. 20:1391–1396, 1992.

    Article  Google Scholar 

  5. Connolly, S. J., Gent, M., Roberts, R. S., et al., CIDS Investigators. Canadian Implanted Defibrillator Study (CIDS). A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101:1297–1302, 2000.

    Google Scholar 

  6. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators, A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N. Eng. J. Med. 337:1576–1583, 1997.

    Article  Google Scholar 

  7. Moss, A. J., Hall, W. J., Cannom, D. S., et al., Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease and high risk for ventricular arrhythmia. N. Engl. J. Med. 335:1933–1944, 1996.

    Article  Google Scholar 

  8. Siebels, J., Kuck, K. H., and CASH Investigators, Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am. Heart J. 127:1139–1144, 1994.

    Article  Google Scholar 

  9. Bigger, J. T., Whang, W., Rottman, J. N., et al., Mechanisms of death in the CABG Patch trial: a randomized trial of implanted cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass grafting surgery. Circulation 99:1416–1421, 1999.

    Google Scholar 

  10. Kadish, A., Dyer, A., Daubert, J. P., et al., Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N. Eng. J. Med. 350:2151–2158, 2004.

    Article  Google Scholar 

  11. Lee, K. L., Hafley, G., Fisher, J. D., et al., Multicenter Unsustained Tachycardia Trial Investigators. Effect of implantable defibrillators on the arrhythmic events and mortality in the Multicenter Unsustained Tachycardia Trial. Circulation 106:233–238, 2002.

    Article  Google Scholar 

  12. National Center for Health Statistics, Health, United States, 2002: with chartbook on trends in the health of Americans. National Center for Health Statistics (DHHS publication no.): Hyattsville, MD, 2002.

  13. Schron, E. B., et al., Quality of life in the Antiarrhythmics Versus Implantable Defibrillators Trial. Circulation 105:589–594, 2002.

    Article  Google Scholar 

  14. Brugada, J., Brugada, R., and Brugada, P., Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation 97:457–460, 1998.

    Google Scholar 

  15. Belhassen, B., Viskin, S., and Antzelevitch, C., The Brugada syndrome: is an implantable cardioverter defibrillator the only therapeutic option? Pacing Clin. Electrophysiol. 25:1634–1640, 2002.

    Article  Google Scholar 

  16. Alings, M., Dekker, L., Sadee, A., and Wilde, A., Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin. Electrophysiol. 24:1420–1422, 2001.

    Article  Google Scholar 

  17. Antzelevitch, C., Brugada, P., Brugada, J., Brugada, R., Nademanee, K., and Towbin, J. A., Clinical approaches to tachyarrhythmias. The Brugada syndrome. Futura: Armonk, NY, 1999.

    Google Scholar 

  18. Koonlawee Nademanee, M. D., et al., Defibrillator versus β-blockers for unexplained death in Thailand (DEBT). Circulation 107:2221–2226, 2003.

    Article  Google Scholar 

  19. Bernard belhassen, M. D., Aharon Glick, M. D., and Sami Viskin, M. D., Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 110:1731–1737, 2004.

    Article  Google Scholar 

  20. Hermida, J. S., Denjoy, I., Clerc, J., et al., Hydroquinidine therapy in Brugada syndrome. J. Am. Coll. Cardiol. 43:1853–1860, 2004.

    Article  Google Scholar 

  21. Hauser, R. G., The growing mismatch between patient longevity the service life of implantable cardioverter-defibrillators. J. Am. Coll. Cardiol. 45(12):2022–2025, 2005.

    Article  Google Scholar 

  22. Gabry, M. D., Brodman, R., Johnston, D., et al., Automatic implantable cardioverter-defibrillator: patient survival, battery longevity and shock delivery analysis. JACC 9(6):1349–1356, 1987.

    Google Scholar 

  23. Fryback, D. G., Dasbach, E. J., Klein, R., et al., The Beaver Dam health outcomes study: initial catalog of health state quality factors. Med. Decis. Mak. 13:89–102, 1993.

    Article  Google Scholar 

  24. Lipscomb, J., Weinstein, M. C., and Torrance, G. W., In: Gold, M. R., Siegel, J. E., Russell, L. B., and Weinstein, M. C., (Eds.), Cost Effectiveness in Health and Medicine. New York: Oxford University Press, 214–246, 1996.

    Google Scholar 

  25. Belhassen, B., Viskin, S., Fish, R., et al., Effects of electrophysiologic-guided therapy with class 1A antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J. Cardiovasc. Electrophysiol. 10:1301–1312, 1999.

    Article  Google Scholar 

  26. Belhassen, B., Shapira, I., Shoshani, D., et al. Idiopathic ventricular fibrillation: inducibility and beneficial effects of class I antiarrhythmic agents. Circulation 75:809–816, 1987.

    Google Scholar 

  27. Hohnloser, S. H., Kuck, K. H., Dorian, P., et al., Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N. Engl. J. Med. 351:2481–2488, 2004.

    Article  Google Scholar 

  28. Bristow, M. R., Saxon, L. A., Boehmer, J., et al., Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. 350:2140–2150, 2004.

    Article  Google Scholar 

  29. Buxton, A. E., Lee, K. L., Fisher, J. D., Josephson, M. E., Prystowsky, E. N., and Hafley, G., A randomized study of the prevention of sudden death in patients with coronary artery disease. N. Engl. J. Med. 341:1882–1890, 1999. [Erratum, N Engl J Med 2000; 342:1300].

    Article  Google Scholar 

  30. Litovsky, S. H., and Antzelevitch, C., Differences in the electrophysiological response of canine ventricular subendocardium and subepicardium to acetylcholine and isoproterenol. A direct effect of acetylcholine in ventricular myocardium. Circ. Res. 67:615–627, 1990.

    Google Scholar 

  31. Suzuki, H., Torigoe, K., Numata, O., and Yazaki, S., Infant case with a malignant form of Brugada syndrome. J. Cardiovasc. Electrophysiol. 11:1277–1280, 2000.

    Article  Google Scholar 

  32. Tanaka, H., Kinoshita, O., Uchikawa, S., Kasai, H., Nakamura, M., Izawa, A., Yokoseki, O., Kitabayashi, H., Takahashi, W., Yazaki, Y., Watanabe, N., Imamura, H., and Kubo, K., Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome. Pacing Clin. Electrophysiol. 24:1293–1294, 2001.

    Article  Google Scholar 

  33. Nademanee, K., Veerakul, G., Nimmannit, S., Chaowakul, V., Bhuripanyo, K., Likittanasombat, K., Tunsanga, K., Kuasirikul, S., Malasit, P., Tansupasawadikul, S., and Tatsanavivat, P., Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 96:2595–2600, 1997.

    Google Scholar 

  34. Antzelevitch, C., Brugada, P., et al., Brugada Syndrome Report of the second consensus conference. Circulation 111:659–670, 2005.

    Article  Google Scholar 

Download references

Acknowledgment

This study was supported by The Hori Information Science Promotion Foundation in Japan.

Author information

Authors and Affiliations

  1. Department of Medical Information and Management Science, Graduate School of Medicine, Nagoya University, 65 Tsurumai, Showa-Ku, 466-8550, Nagoya, Japan

    Kai Wang, Kazunobu Yamauchi, Hiroki Kato & Ken Kato

  2. Department of Cardiology, Graduate School of Medicine, Nagoya University, Nagoya, Japan

    Ping Li

  3. Healtheconomics Research Group, Tokyo, Japan

    Makoto Kobayashi

  4. Higashi Municipal Hospital of Nagoya City, Nagoya, Japan

    Yoshiyuki Shimizu

Authors
  1. Kai Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazunobu Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ping Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroki Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Makoto Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ken Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshiyuki Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kai Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, K., Yamauchi, K., Li, P. et al. Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Brugada Syndrome Treatment. J Med Syst 32, 51–57 (2008). https://doi.org/10.1007/s10916-007-9107-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10916-007-9107-7

Keywords

Search

Navigation